A newly developed vaccine to treat patients with metastatic HER2-positive cancers has been found to be effective and safe, scientists say. The trial showed that among the 11 evaluable patients, those who received more than the lowest dose of the HER2-targeted cancer vaccine, six (54%) demonstrated clinical benefits.
